Skip to main
ABEO
ABEO logo

Abeona Therapeutics (ABEO) Stock Forecast & Price Target

Abeona Therapeutics (ABEO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abeona Therapeutics has projected top-line revenues of approximately $32 million for 2025, which are expected to increase significantly to $130.4 million in 2026, indicating a strong growth trajectory. The company's favorable market access situation could enhance coverage and drive additional revenue, contributing to an optimistic outlook for the future. Furthermore, the potential of its pipeline assets in gene therapies and treatments for rare genetic diseases may provide further incremental upside to financial forecasts.

Bears say

Abeona Therapeutics faces significant risks that could adversely impact its financial outlook, primarily due to the anticipated slower than projected uptake of pz-cel in the United States following its market introduction. Additionally, the company's ability to optimize the value of pz-cel outside the U.S. remains uncertain, raising concerns about revenue potential and market access. Furthermore, setbacks in earlier-stage pipeline programs and the possibility of long-term dilution risk for shareholders contribute to an overall negative outlook on the company's stock.

Abeona Therapeutics (ABEO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abeona Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abeona Therapeutics (ABEO) Forecast

Analysts have given Abeona Therapeutics (ABEO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Abeona Therapeutics (ABEO) has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abeona Therapeutics (ABEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.